Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk, Eli Lilly, and others are advancing obesity drugs, with key data expected for assets including CagriSema, ...

Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

An anxious generation turns to functional foods and beverages and alternative medicine, inspiring better-for-you innovation.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

The commission recommends a shift away from relying solely on BMI to more accurately define obesity as a disease.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...